ALTTO No More Than a Detour for HER2+ Breast CancerALTTO No More Than a Detour for HER2+ Breast Cancer

Dr Lidia Schapira weighs in on the results of the ALTTO trial in HER2-positive breast cancer in which dual therapy using trastuzumab plus lapatinib proved disappointing. Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news